Erlotinib Response in a Non-Small Cell Lung Cancer Patient with EGFR Exon 20 Mutation.

The article discusses a study on erlotinib response in a smoker Turkish male with metastatic lung adenocarcinoma characterized by a rare exon 20 mutation. Topics include the confirmation that epidermal growth factor receptor (EGFR)-activating mutations represents the main predictor of clinical outcome with tyrosine kinase inhibitor (TKI) therapy, a case report showing a good clinical response to erlotinib after platinum-based chemotherapies, and conclusion on EGFR exon 20 mutations.